Coronary Artery Calcium (CAC) Scoring: Agatston Methodology, Statin Allocation, and ASCVD Risk Refinement

Principles of Non-Contrast Computed Tomography Calcium Scoring

Atherosclerotic plaque calcification is an active, regulated biological process that mirrors osteogenesis, occurring exclusively within diseased coronary arteries. Early lipid-rich atheromas develop microcalcifications within necrotic lipid cores as vascular smooth muscle cells undergo osteogenic differentiation. Over decades, these coalesce into macroscopic hydroxyapatite crystalline calcifications visible on radiological imaging. The amount of calcified plaque is directly proportional to the total coronary atherosclerotic burden.

Coronary Artery Calcium (CAC) scoring is performed using prospective electrocardiographically (ECG)-gated, non-contrast low-dose computed tomography (typically delivering <1.0 millisievert of radiation—equivalent to a standard mammogram). Imaging is acquired during mid-to-late diastole (when cardiac motion is minimal), slicing through the coronary tree from the carina to the base of the heart.

The Agatston Scoring Methodology

Developed by cardiologist Arthur Agatston, the Agatston Scoring System is the global quantitative standard: - Technical Calculation: A calcified lesion is defined on CT as an area of at least 1 mm² exhibiting a CT attenuation density ≥130 Hounsfield Units (HU). The area of each calcified plaque in the left main, left anterior descending (LAD), circumflex, and right coronary artery is multiplied by a density weighting factor (1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for ≥400 HU). The sum of all lesions across all four arteries yields the total Agatston score.

Clinical Risk Categories: 1. CAC = 0: No identifiable calcified coronary plaque. 2. CAC 1 to 99: Mild calcified plaque burden. 3. CAC 100 to 399: Moderate plaque burden; confirmed clinical atherosclerosis. 4. CAC ≥400 (or ≥75th percentile for age and sex): Severe plaque burden; high likelihood of significant luminal stenosis and high future event rates.

The 'Power of Zero' and Statin De-Prescribing

One of the most powerful diagnostic findings in preventive cardiology is a CAC score of Zero. Landmark data from the Multi-Ethnic Study of Atherosclerosis (MESA)—a prospective cohort following thousands of participants over decades—established the 'Power of Zero': - In asymptomatic individuals with an intermediate 10-year ASCVD risk (7.5% to 20%), a CAC score of 0 predicts an annual cardiovascular event rate of <0.1% per year and an all-cause 10-year event rate below 3%. - Statin Deferral: Current ACC/AHA guidelines establish that for intermediate-risk individuals with a CAC = 0, statin therapy may be safely deferred, with re-screening scheduled in 5 years (the 'warranty period' of a zero score), provided the patient is a non-smoker, has no diabetes, and has no family history of premature CAD.

Clinical Indications for Statin and Aspirin Allocation

Conversely, discovering elevated coronary calcium reclassifies patient risk upward, driving aggressive medical optimization: - CAC 1 to 99: Reclassifies patients to higher risk; statin therapy is strongly recommended, especially in patients aged ≥55 years. - CAC ≥100 (or ≥75th percentile): Reclassifies the patient into the highest primary prevention tier. Guidelines unequivocally mandate: 1. High-Intensity Statin Therapy (Atorvastatin 40-80 mg or Rosuvastatin 20-40 mg daily) to stabilize fibrous caps and reduce systemic vascular inflammation. 2. Low-Dose Aspirin (81 mg daily): While routine aspirin is no longer recommended for broad primary prevention due to bleeding risks, patients with CAC ≥100 have a high net clinical benefit, where the absolute reduction in myocardial infarction far outweighs gastrointestinal bleeding risk. 3. Blood Pressure and Lifestyle: Strict blood pressure optimization targeting <130/80 mmHg.